Ah, the stock market. A bastion of rational exuberance, or so we’re told. That is, until former President Donald J. Trump decides to weigh in. In what has become a familiar, albeit consistently bewildering, dance, the markets once again found themselves whipsawed by a flurry of pronouncements, threats, and “great deals” emanating from the Trump orbit this past week. Investors, bless their optimistic hearts, continue to parse every tweet and press conference, attempting to discern whether the latest policy pronouncement is a harbinger of doom or a golden opportunity. The only constant, it seems, is the delightful unpredictability.
Monday, September 22, 2025, offered a microcosm of this chaotic charm. While the major U.S. indexes, including the Dow Jones Industrial Average, the S&P 500, and the Nasdaq Composite, managed to claw their way to new all-time highs for the third consecutive session, the underlying currents were anything but calm. The S&P 500 rose 0.4% to 6,693.75, the Dow added a modest 0.1% to 46,381.54, and the tech-heavy Nasdaq surged 0.7% to 22,788.98. One might assume this indicates widespread market confidence, but a closer look reveals a narrative as convoluted as a Trumpian trade negotiation.
The Art of the Deal (or Threat)
First, the carrot. President Trump, ever the dealmaker, announced an $8 billion agreement for Uzbekistan Airways to acquire up to 22 Boeing 787 Dreamliners. This, he declared, would create over 35,000 jobs in the United States. Naturally, Boeing shares, which had closed down 1.65% at $212.09 on Monday, September 22, 2025, in regular trading, rallied in after-hours trading, with retail sentiment on Stocktwits turning “extremely bullish”. Analysts quickly chimed in, suggesting a positive ripple effect for industrial ETFs such as the Vanguard Industrials ETF, Industrial Select Sector SPDR Fund, and iShares U.S. Industrials ETF. Because nothing says stability like a single, massive aircraft order announced via social media, immediately reversing a day of losses. It’s almost as if the market is a puppy, eagerly awaiting its next treat or scolding.
Then, the stick. Or, in this case, a whole forest of them. The administration’s penchant for tariffs continued to sow seeds of uncertainty. A renewed threat emerged regarding tariffs on chip imports from firms not producing in the U.S.. While specific market reactions to this particular threat on September 23rd were still developing, the semiconductor sector has long been a nervous bystander in the trade wars. Earlier analyst comments, for instance, noted that while some domestic sectors might benefit from protectionist policies, “globalized tech firms like ASML face headwinds”. The semiconductor industry, with its intricately globalized supply chains, remains perpetually on edge, wondering when the next hammer will drop and from which direction.
Pharmaceutical companies also found themselves squarely in the crosshairs. The Trump administration’s aggressive drug pricing reforms and tariff policies have been a consistent source of market volatility. While some of the more extreme threats, such as tariffs reaching 250% on pharmaceutical imports, were reportedly scaled back to 15% after negotiations with the European Union, the specter of protectionism looms large. Indian pharmaceutical companies, in particular, have felt the sting. In late July and early August 2025, shares of Indian drugmakers declined after President Trump announced a 25% tariff on Indian exports, with hints of further duties on drug exports to come. The Nifty Pharma index dropped between 0.66% and 1.5% in response to these announcements. On September 22, 2025, Pfizer shares were down 0.81%, reflecting the broader industry’s struggle with “uncertainty over Medicare/Medicaid policies, tariffs on pharmaceutical companies and pressure from US president Donald Trump to cut drug prices for Americans,” as one fund manager so eloquently put it. The S&P 500 Pharmaceuticals Index has already dropped 5% year-to-date, a testament to this ongoing regulatory tightrope walk. It seems the only thing predictable about drug prices is their unpredictability under the current policy regime.
Immigration Policy: A Tech Headache
Adding another layer of intrigue to the market’s already complex tapestry was the administration’s latest move on immigration. The announcement of a hefty $100,000 annual fee for new H-1B visas, aimed at “protecting American jobs,” sent ripples through the technology sector. U.S. tech shares, despite the broader market’s gains, “slipped on Monday” due to concerns over escalating labor costs and restricted access to skilled workers. Major tech giants and prominent H-1B sponsors like Microsoft, Amazon, Alphabet, and Goldman Sachs reportedly issued urgent travel advisories to their employees. Shares of companies heavily reliant on H-1B visas, such as Cognizant Technology Solutions, JP Morgan, and Intel, saw declines of 1.2% to 1.6% in premarket trading on September 22.
The impact was particularly acute on Indian IT stocks, which form the backbone of many H-1B applications. The Nifty IT index plummeted over 3% in early trade on Monday, September 22, dragging down major players like Tata Consultancy Services (-2%), Infosys (-2% to Rs 1,510.20), Wipro (-3%), and Tech Mahindra (-6%). Jefferies analysts warned that this “talent supply crunch” could squeeze corporate profits by 4-13%. However, in a classic display of market contrarianism, some analysts, like those at Motilal Oswal Financial Services, suggested this shift could actually benefit domestic tech companies by forcing a reliance on more cost-effective offshore work, potentially improving operating margins. Because nothing says innovation like making it prohibitively expensive to hire the best global talent, only to then declare it a win for domestic efficiency. The Nasdaq Composite, ever the enigma, still managed to close up 0.7% on Monday, largely buoyed by unrelated news of Nvidia‘s partnership with OpenAI and an Apple price target hike. It seems even a self-inflicted tech talent wound couldn’t completely derail the AI-fueled enthusiasm.
Analyst Whining and Investor Whipsawing
The market’s reaction to these policy pronouncements is a spectacle in itself. Analysts, perpetually caught between explaining the inexplicable and predicting the unpredictable, continue to highlight the persistent volatility. “Uncertainty,” as one report from September 16, 2025, noted, “has been the watchword of 2025”. Another from September 12, 2025, predicted “persistent market volatility and higher inflation, driving long-term elevated interest rates”. It’s a testament to the market’s resilience, or perhaps its sheer exhaustion, that it continues to find reasons to hit new highs amidst such a turbulent policy landscape.
Beyond the grand pronouncements, even more niche presidential comments can send specific stocks reeling. Case in point: Kenvue (KVUE), the maker of Tylenol, saw its shares drop a significant 7.5% on Monday, September 22, 2025, following reports that the Trump administration was set to announce an alleged link between Tylenol use during pregnancy and autism. Kenvue, for its part, quickly asserted that scientific studies show no such link. Yet, a presidential suggestion, however unsubstantiated, was enough to wipe out a chunk of its market capitalization. Meanwhile, safe-haven assets like gold continued their ascent, with futures up 2% to a record-high $3,780 an ounce on Monday. Because when policy becomes performance art, sometimes the only safe bet is something shiny and inert.
In conclusion, the stock market under the influence of Donald Trump remains a fascinating, if not entirely rational, beast. It’s a market where an $8 billion deal can be announced on a social media platform, reversing a stock’s daily decline, while simultaneously, a $100,000 visa fee sends an entire tech sub-index tumbling. It’s a world where threats of tariffs on crucial imports coexist with record-setting rallies driven by AI enthusiasm. For investors, the message is clear: buckle up, expect the unexpected, and perhaps keep a close eye on Truth Social. Because in this market, the only truly consistent thing is the delightful chaos, served with a side of snark, and always, always, on the edge of its seat.
DISCLAIMER: We read Trump’s posts so you don’t have to. This is comedy meets market data, not financial advice. Not political advice either – we just like charts and chaos.
Elana Harper is a seasoned financial editor and market analyst with over a decade of experience covering global equities, economic trends, and corporate earnings. Known for her sharp insights, Elana specializes in making complex financial topics accessible to a broad audience. She now serves as the Senior Financial Editor at Stock Market Watch, where she oversees daily market coverage and political commentary.